tion between ARC/IRCand the presence of nephropathy, neuropathy and retinopathy in the 4 groups were examined. Responses of aldosterone and its precursors, 1 1 -desoxycorticosterone (DOC), corticosterone (B) and 18-hydroxy-corticosterone
(1 8-OH-B) to ACTHor angiotensin II (A II) were measured in normal subjects and in the 4 groups of diabetic patients in order to examineadrenal biosynthesis in this disorder.
PRA in the diabetic patients was elevated to 2.4±2.2 from 0.8±0.6 ng/ml/h (3.2±1.7 from 1.2± 0.7 in normals) 2 h after furosemide (1 mg/kg) in an upright position. ARC was 15.8±3.3, 9.0±3.0, 13.7+2.2 and 17.4±3.0 pg/mlin diabetic groups I-IV, respectively (23.7±4.6 pg/ml in normals and 17.2 ± 3.9 pg/ml in chronic glomerulonephritis). On the other hand, IRC showed a high value of 323.1±87.5 pg/ml only in group IV (141. 8±35.6 in normals, 149.5± 17.2 in chronic glomerulonephritis).
The ARC/IRC ratio after captopril administration was, therefore, low in group IV, but not in the other groups of diabetics.
The factor most strongly correlated with the ARC/IRCratio was the creatinine clearance in the nephritis group but not in diabetic group IV. PAC was 7.5±2.6, 6.0±1.6, and 4.7±2.4 ng/100mlin groups I, II, and III and IV (N 7.7±2.2 ng/100 ml), respectively, despite normal potassium concentrations (4.3 ± 0.1 meq/1). 18-OH-B in diabetic patients with neuropathy and nephropathy (8.8 ± 3.2 ng/100 ml) was significantly lower than that in controls. No difference in B, DOC, or F (cortisol) was observed between diabetic patients and controls.
Infusions of ACTHor A II were associated with low aldosterone and 18-OH-Bresponses in group IV. B, DOCand F were increased both in diabetic patients and in controls; there was no significant difference between diabetic patients and controls in these 3 steroids after ACTHand A II, also suggesting that the defect is probably at the level of the zona glomerulosa cell. HSHAwas found in 3 elderly diabetic patients with nephropathy or autonomic neuropathy of group IV and there was no significant difference in female/male ratio. A HSHA patient, in whom renal function was extremely weakened and hyperkalemia persisted, underwent an examination after 2 yr. PACwas within the normal range (6.0-10.9 ng/100 ml) and was positively correlated with the serum potassium level (r = 0.62, n=22). PACrose from 10.9 to 15.8 ng/100 ml after A II and from 6.0 to 14.2 ng/100 ml after ACTH. In another HSHApatient, microscopic examination at autopsy showed severe atrophy of the zona glomerulosa and the outer layer of the zon^t fasciculata of the adrenals, hyalinization of the glomeruli, and destruction of the juxtaglomerular apparatus.
These findings suggest that, in diabetic patients, first impairment of the A II receptor occurs, and secondly corticosterone methyloxidase I and II are pathies remains undetermined, a randomized prospective study was conducted to clarify the relationship between the degree of glycemic control and the progression of diabetic microangiopathies. In addition, the method of insulin injection to non-obese non-insulin dependent diabetic patients (NIDDM)
with secondary failure on sulfonylureas in order to strictly glycemias was investigated.
Four-year randomized prospective study A randomized prospective study was undertaken to determine the glycemic threshold in 50 In MIT it increased significantly, from 23.2± 1.8 U/day to 39.8±2.6 U/day at 48 months. In CIT, there was no significant change in urinary excretion of total protein. In MIT, it decreased markedly from the control value of 587± 112 mg/day to 130±39, 128±46, and 65 ±25 mg/day at 3, 12 and48 months later. Since systolic and diastolic blood pressure did not change during the period in either group, these improvements seemed to be affected by glycemic control. On the other hand, the urinary excretion of /32-microglobulin did not change significantly in either group. The motor nerve conduction velocity between the elbow and the wrist showed no significant change at any point and maintained a low value in CIT. In MIT, it showed a gradual but significant improvement at every point; from 47. From these results, it was demonstrated that the glycemic threshold is an HbAi level of lower than 8%. These results may be indicative that strict glycemic control should be initiated at an early stage or at the functionally abnormal stage of microangiopathies.
Effectiveness ofprandial insulin supplementation in NIDDMwith secondary failure to sulfonylurea It is of no doubt that a therapeutic tool which enhances hepatic glucose uptake, especially after meal-intake, should be utilized for strict glycemic control in diabetics.
In animal experiments, we demonstrated that portally administered insulin enhances a muchgreater hepatic uptake than that administered peripherally (2) . Wealso showed that the hepatic glucose uptake obtained with intraportal or intrahepatic artery glucose infusion was markedly higher than that with peripheral glucose infusion, indicating that the hepatic-general circulatory glucose gradient might be an indicator of hepatic glucose uptake (3). In addition, we recently found that the hepatic glucose uptake is greater if the peripheral glucose concentration is maintained euglycemic rather than hyperglycemic, even though the gradient was equivalent (unpublished). From the viewpoint of insulin secretion, NIDDM is characterized by a decreased glycemic rise-related insulin secretion but with substantial amount of basal insulin is preserved (4) . Recently, we have clearly demonstrated that sufficient insulin supplements before each meal in NIDDM normalized meal-related glycemic excursions, prevent beta cell exhaustion followed by restoration of endogenous basal insulin secretion (5).
From these combined results, we have proposed the following working hypothesis in the treatment regime of non-obese NIDDMwith secondary failure on sulfonylureas (Fig. 2 ). This hypothesis was tested in 77 non-obese NIDDMwith secondary failure on long-term sulfonylurea treatment. The age of the patients was 58.3 ± ll.4 (mean±SD) yr. The duration of diabetes averaged 18.4± 6.5 yr and duration of sulfonylurea treatment was 8. 4 breakfast, 7.0 ±0.5 U for lunch, and 7.4±0.6 U for dinner , respectively. Urinary C-peptide excretion rate (UCPR), during the period from ll PMto 7 AM in these patients was 1.83 ±0.ll ug/h before insulin treatment and 1.85 ±0.18 fig/h at 4 wk of treatment. However, UCPRdivided by plasma glucose area (1 1 PM-7 AM) was increased by twofold in 4 wk.
In 21 cases, even though pre-and post-meal glycemias were regulated, pre-breakfast glycemias were higher than 150 mg/dl. In 14 out of 21 cases with combined insulin and bedtime glibenclamide therapy, the perfect glycemic excursions were established. In those 14 patients, with insulin injection alone, UCPRwas 0.56 ± 0.49 //g/h. However, after adding glibenclamide, UCPR during night increased to 1.50±0.64 ,«g/h, showing that glibenclamide again stimulates basal insulin secretion. In the other 7 patients, pre-dinner or bedtime intermediate-acting insulin injection was obligatory in addition to pre-meal regular insulin to perfectly regulate the glycemia level. With these treatments, even though insulin requirements decreased week by week, HbAic decreased rather rapidly; 9.5 ±0.6, 7.9±0.6, 7.2±0.4%, after 1, 3, and 6 months, respectively. Thus, these studies clearly demonstrate that in NIDDM, endogenous basal insulin secretory ability is reversed dynamically and insulin sensitivity is modified in response to glycemic regulation as well.
In summary, to prevent onset or progress in diabetic microangiopathies, it is of necessity to regulate the blood glucose excursions to the same extent as healthy subjects, even in the early stage of diabetes. Maintenance of strict glycemic regulation, in turn, facilitates ease in the treatment of diabetes with the aid of preserved insulin secretion and diminished insulin resistance.
